Please contact your representative at Oppenheimer & Co to request a 1-on ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on ...

As of March 4, 2025, the average one-year price target for Abeona Therapeutics is $16.22/share. The forecasts range from a low of $9.60 to a high of $22.05. The average price target represents an ...

As of March 4, 2025, the average one-year price target for Abeona Therapeutics is 16.12 GBX/share. The forecasts range from a low of 9.54 GBX to a high of 21.92 GBX. The average price target ...

Oppenheimer & Co. Inc. acquired a new stake in StepStone Group LP (NASDAQ:STEP – Free Report) during the 4th quarter, ...

Oppenheimer Asset Management Inc. acquired a new stake in shares of Texas Capital Bancshares, Inc. (NASDAQ:TCBI – Free Report ...

Oppenheimer Asset Management Inc. reduced its position in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 72.3% in the 4th ...

Oppenheimer Asset Management Inc. cut its holdings in Gibraltar Industries, Inc. (NASDAQ:ROCK – Free Report) by 37.5% during ...

Oppenheimer Asset Management Inc. purchased a new stake in Embecta Corp. (NASDAQ:EMBC – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 10,097 ...

Oppenheimer Asset Management Inc. acquired a new position in shares of VSE Co. (NASDAQ:VSEC – Free Report) in the fourth ...

Oppenheimer Asset Management Inc. lowered its stake in Huntington Bancshares Incorporated (NASDAQ:HBAN – Free Report) by 18.8% during the 4th quarter, according to the company in its most recent ...

Oppenheimer Asset Management Inc. acquired a new stake in shares of ZoomInfo Technologies Inc. (NASDAQ:ZI – Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The ...

Oppenheimer Asset Management Inc. lessened its position in iRhythm Technologies, Inc. (NASDAQ:IRTC – Free Report) by 44.3% ...